Viatris Inc.
https://www.viatris.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Viatris Inc.
Gilead Seals VLs For Lenacapavir Amid Concerns Around Price, API Supplies
Gilead strikes voluntary licensing agreements with six generic manufacturers for lenacapavir but health groups seek clarity on pricing and seeming API supply restrictions. All eyes are also on the patent opposition case in India.
Finance Watch: More Than $4.2bn Raised Across Four New VC Funds
Private Company Edition: ARCH raised more than $3bn for its eighth fund, Frazier added $630m to its public fund that also can back crossover rounds, DCVC’s third biotech fund totaled $400m and Asabys raised €180m ($200m) for its second fund. Also, Aktis closed a $175m series B round.
US Generics Players Enjoy Calmer Waters
After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape.
Generics Bulletin Explains: US Generics Players Enjoy Calmer Waters
After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape. Generics Bulletin looks at the latest trends.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
-
Drug Delivery
- Transdermal
- Other Names / Subsidiaries
-
- Acton Pharmaceuticals, Inc.
- Agila, Bioniche Pharma Holdings Limited
- Alaven Pharmaceutical, LLC
- Antula Healthcare AB
- Bertek
- Dow B. Hickham
- Dow Hickam Pharmaceuticals, Inc.
- Famy Life Sciences
- Generics (UK) Ltd.
- Jai Pharma
- Madaus Pharma
- Meda AB
- Meda Pharmaceuticals Inc.
- Mylan Inc.
- Mylan Laboratories Limited (formerly Matrix Laboratories Limited)
- Mylan Specialty (formerly Dey Pharma L.P.)
- Rottapharm Madaus
- Mylan Technologies, Inc.
- Oyster Point Pharma, Inc.
- UDL Laboratories
- Viatris Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice